SYNB-8802 is under clinical development by Synlogic and currently in Phase I for Secondary Hyperoxaluria. According to GlobalData, Phase I drugs for Secondary Hyperoxaluria does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the SYNB-8802 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SYNB-8802 overview
SYNB-8802 is under development for the treatment of enteric hyperoxaluria. It is a consortia of engineered non-pathogenic strain of E. coli (Nissle), designed from natural probiotic bacteria that are engineered using synthetic biology and microbiome platform. The drug candidate is administered through oral route.
Synlogic overview
Synlogic is a clinical stage drug development company that develops novel class of living medicines for the treatment of rare and genetic metabolic diseases. The company’s pipeline includes SYNB1618 to treat Phenylketonuria. It also produces drugs based on its proprietary synthetic biology and microbiome platform for the treatment of diseases, including liver disease, inflammatory and immune disorders, and cancer. The company’s synthetic biotics make therapeutic. The company works in partnership with pharmaceutical and biotechnology companies for novel drug development in major disease areas. Synlogic is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of SYNB-8802’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
